Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Truist Securities Downgrades Aptinyx to Hold

Truist Securities Downgrades Aptinyx to Hold

Truist Securities analyst Joon Lee downgrades Aptinyx (NASDAQ:APTX) from Buy to Hold.

byBenzinga Newsdesk

August 16, 2022

1 minute read

Truist Securities analyst Joon Lee downgrades Aptinyx (NASDAQ:APTX) from Buy to Hold.

IQVIA Q2: 5.3% Sales Growth, Additional Share Repurchase, Reduced FY23 Guidance & More

By Nabaparna Bhattacharya

August 1, 12:29 PM

IQVIA Holdings, Inc. (NYSE: IQV) posted Q2 sales of $3.728 billion, up 5.3% Y/Y on a reported basis and 5.5% at constant currency (CC),

IQV

Analyst Ratings

What 6 Analyst Ratings Have To Say About RH

By Benzinga Insights

March 24, 11:00 AM

Over the past 3 months, 6 analysts have published their opinion on RH (NYSE:RH) stock. These analysts are…

Truist Securities Maintains Hold on SITE Centers, Lowers Price Target to $14

By Benzinga Newsdesk

December 5, 9:55 AM

Truist Securities analyst Ki Bin Kim maintains SITE Centers (NYSE:SITC) with a Hold and lowers the price target from $15 to $14.

SITC

Two Pot Companies Continue To Focus On Cannabinoid-Based Self-Emulsifying Drug Delivery Systems

By Vuk Zdinjak

June 26, 9:36 AM

Avicanna Inc. (OTCQX: AVCNF) (TSX:AVCN) (FSE:0NN) announced the extension of its existing strategic manufacturing agreement with Medipharm Labs Inc. (OTCQB: MEDIF) for the commercialization of Avicanna’s p

AVCNF

Truist Securities Downgrades Aptinyx to Hold

Related Posts

IQVIA Q2: 5.3% Sales Growth, Additional Share Repurchase, Reduced FY23 Guidance & More

What 6 Analyst Ratings Have To Say About RH

Truist Securities Maintains Hold on SITE Centers, Lowers Price Target to $14

Two Pot Companies Continue To Focus On Cannabinoid-Based Self-Emulsifying Drug Delivery Systems